These clinical observations raise the intriguing possibility of exploiting the discovery of small-molecule inhibitors that incapacitate specific serpins to enhance the response of SERPINB3-expressing tumor cells to cancer therapeutics, irradiation, or lysoptosis inducers. The gene discussed is SERPINB3; the disease is neoplasm.